We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+6.29%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$121B
AUM Growth
+$6.29B
Cap. Flow
+$257M
Cap. Flow %
0.21%
Top 10 Hldgs %
24.67%
Holding
4,045
New
183
Increased
1,650
Reduced
1,805
Closed
213

Sector Composition

Rank Sector Weight
1 Technology 15.49%
2 Financials 8.61%
3 Healthcare 8.48%
4 Industrials 6.86%
5 Consumer Discretionary 5.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FL
3251
DELISTED
Foot Locker
FL
$302K ﹤0.01%
+11,126
New +$379K
ATRA icon
3252
Atara Biotherapeutics
ATRA
$80.7M
$302K ﹤0.01%
7,494
-62
-0.8% -$3.51K
TMDV icon
3253
ProShares Russell US Dividend Growers ETF
TMDV
$4.85M
$302K ﹤0.01%
6,433
+348
+6% +$16K
IRTC icon
3254
iRhythm Holdings
IRTC
$3.96B
$300K ﹤0.01%
2,880
+187
+7% +$22.5K
BTG icon
3255
CALL
B2Gold
BTG
$6.79B
$300K ﹤0.01%
120,000
SG icon
3256
Sweetgreen
SG
$656M
$300K ﹤0.01%
+23,370
New +$216K
DCH
3257
Dauch Corp
DCH
$1.65B
$299K ﹤0.01%
36,149
+46
+0.1% +$341
VCV icon
3258
Invesco California Value Municipal Income Trust
VCV
$527M
$299K ﹤0.01%
31,200
+7,500
+32% +$72.7K
AFRM icon
3259
Affirm
AFRM
$26.1B
$298K ﹤0.01%
19,437
-2,502
-11% -$33.2K
BBIO icon
3260
BridgeBio Pharma
BBIO
$16.3B
$297K ﹤0.01%
+17,291
New +$260K
EQWL icon
3261
Invesco S&P 100 Equal Weight ETF
EQWL
$2.79B
$297K ﹤0.01%
3,650
+250
+7% +$19.6K
HOOD icon
3262
Robinhood
HOOD
$85.8B
$297K ﹤0.01%
+29,777
New +$277K
CXE
3263
DELISTED
MFS High Income Municipal Trust
CXE
$297K ﹤0.01%
85,258
+840
+1% +$2.94K
DNLI icon
3264
Denali Therapeutics
DNLI
$3.9B
$296K ﹤0.01%
10,031
-1,376
-12% -$38.7K
BSCW icon
3265
Invesco BulletShares 2032 Corporate Bond ETF
BSCW
$1.52B
$296K ﹤0.01%
+14,704
New +$299K
OSBC icon
3266
Old Second Bancorp
OSBC
$1.3B
$295K ﹤0.01%
22,624
-1,635
-7% -$20.8K
CUBI icon
3267
Customers Bancorp
CUBI
$2.8B
$295K ﹤0.01%
+9,748
New +$218K
IWC icon
3268
iShares Micro-Cap ETF
IWC
$1.5B
$293K ﹤0.01%
2,682
-1,110
-29% -$117K
VZIO
3269
DELISTED
VIZIO Holding Corp.
VZIO
$293K ﹤0.01%
43,371
+2,874
+7% +$22.2K
UPST icon
3270
Upstart Holdings
UPST
$2.93B
$293K ﹤0.01%
8,171
-3,469
-30% -$79.8K
AROC icon
3271
Archrock
AROC
$5.84B
$292K ﹤0.01%
28,480
+209
+0.7% +$2.06K
ESTA icon
3272
Establishment Labs
ESTA
$2.23B
$292K ﹤0.01%
4,250
FSR
3273
DELISTED
Fisker Inc.
FSR
$292K ﹤0.01%
51,693
+6,266
+14% +$36.1K
RVNU icon
3274
Xtrackers Municipal Infrastructure Revenue Bond Active ETF
RVNU
$144M
$291K ﹤0.01%
11,552
-66
-0.6% -$1.65K
IFN
3275
Aberdeen India Fund
IFN
$509M
$291K ﹤0.01%
17,534
+751
+4% +$11.7K

Similar funds

Raymond James & Associates's Q2 2023 Portfolio in Review

As of Q2 2023, Raymond James & Associates held 4,045 positions worth $121B, up 5.5% from $115B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Raymond James & Associates's Q2 2023 filing shows 183 new, 1,650 increased, 1,805 reduced and 213 closed positions. Its largest new stake was Choice Hotels: 212,259 shares worth $24.9M. The largest sale was iShares MSCI USA Min Vol Factor ETF, an estimated $562M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q2 2023 buy was Choice Hotels: 212,259 shares worth $24.9M.
  • Raymond James & Associates added most to iShares Core US Aggregate Bond ETF in Q2 2023, an estimated $753M increase.
  • Raymond James & Associates's biggest Q2 2023 reduction was iShares MSCI USA Min Vol Factor ETF, cutting an estimated $562M.
  • Raymond James & Associates fully exited ABB Ltd in Q2 2023, selling an estimated $17.1M.
  • Raymond James & Associates's ten largest holdings make up 25% of its $121B portfolio in Q2 2023.
  • Raymond James & Associates opened 183 new positions and closed 213 in Q2 2023.
  • Raymond James & Associates's portfolio value rose 5.5% quarter-over-quarter to $121B.

Based on Raymond James & Associates's 13F filing for Q2 2023, filed 25 Jul 2023.